Compare Eli Lilly And Co (LLY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Otis Worldwide Corp — how do they compare? Eli Lilly And Co trades at $1,221.61 (market cap $1.08T), while Otis Worldwide Corp trades at $73.82 (market cap $27.80B). The key difference: Eli Lilly And Co is far larger — about 38.8× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| LLY | OTIS | |
|---|---|---|
Market Cap | $1.08T | $27.80B |
Sector | Health | Industrials |
52-Week High | $1.24K | $93.62 |
52-Week Low | $639.43 | $69.34 |
Enterprise Value | $1.13T | $35.84B |
Dividend Yield | 0.57% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Otis Worldwide (OTIS) trades at $73.58, up 0.97% on the day, with a neutral technical signal. The company reported mixed Q2 2026 results, beating revenue estimates but missing EPS expectations and cutting full-year profit guidance due to margin pressures. Strong service segment growth, particularly in modernization, contrasts with weak new equipment demand. Analyst consensus is divided with a $92.50 price target, suggesting significant upside from current levels.
The outlook balances service-driven revenue momentum against near-term margin headwinds. Investment opportunity lies in Otis's defensive service business and global market leadership, but risks include execution on margin improvement, China exposure, and competitive pressures. Cash flow volatility and high debt levels require monitoring for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
